Categories
Change Password!
Reset Password!
Non-allergic rhinitis can lead to the progression of
eosinophilic, non-IgE-
provoked nasal polyps and
asthma.
Reslizumab (a humanized anti-IL-5 monoclonal antibody) therapy
significantly improved the asthma and nasal symptoms in patients with
eosinophilic asthma associated chronic
rhinosinusitis (CRS) with polyps.
CRS with polyps, often combined with asthma, is linked with
eosinophilic inflammation. N V Boiko et al. evaluated patients with severe
asthma on reslizumab intravenous at a dose of 3 mg/kg once in 4 weeks to study
the effectiveness of reslizumab.
Out of nine patients, 7 had CRS with polyps and 2 patients had chronic
non-allergic rhinitis (NARES) symptoms.
Nasal symptoms via Sino-nasal
Outcome Test (SNOT-22); endoscopic image of nose; variations in the Sinus CT of paranasal sinuses via Lund-Mackay scale;
total polyp score (TPS); rhinocytogram outcomes;
blood eosinophilic cationic
protein and eosinophil levels were studied after 6 months. Decrease
in asthma attacks, systemic corticosteroids usage, spirometry test results and
Asthma Control Test (ACT) were assessed for efficacy of asthma management.
Eight patients showed improvement of nasal symptoms
along with noticeable recovery in asthma control. Patients having CRS with polyps
had more significantly improved asthma. It was possible to identify anamnestic manifestation of NARES symptoms in the early phases of the
disease in these patients.
Vestnik Otorinolaringologii
[Impact of reslizumab on the course of chronic rhinosinusitis in patients with eosinophilic asthma]
N V Boiko et al.
Comments (0)